Trevi Therapeutics, Inc. Quarterly Nonoperating Income (Expense) in USD from Q1 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Trevi Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2018 to Q2 2024.
  • Trevi Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $929K, a 23% decline year-over-year.
  • Trevi Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $4.39M, a 21% increase year-over-year.
  • Trevi Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $4.83M, a 571% increase from 2022.
  • Trevi Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $719K.
  • Trevi Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$1.49M, a 417% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $4.39M $929K -$278K -23% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $4.67M $996K -$159K -13.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $4.83M $1.13M -$2K -0.18% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-20
Q3 2023 $4.83M $1.33M +$1.2M +911% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $3.63M $1.21M +$1.44M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $2.18M $1.16M +$1.46M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $719K $1.13M +$1.39M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-20
Q3 2022 -$666K $132K +$438K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$1.1M -$236K +$393K +62.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$1.5M -$309K -$12K -4.04% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$1.49M -$253K +$60K +19.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 -$1.55M -$306K -$161K -111% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$1.38M -$629K -$643K -4593% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$741K -$297K -$454K -289% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$287K -$313K -$538K -239% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-17
Q3 2020 $251K -$145K -$425K -152% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $676K $14K -$52K -78.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $728K $157K +$151K +2517% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 $577K $225K +$327K Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 $250K $280K +$1M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$752K $66K +$569K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$1.32M $6K +$940K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$2.26M -$102K Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$722K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$503K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-12
Q1 2018 -$934K Jan 1, 2018 Mar 31, 2018 10-Q 2019-06-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.